Table 2.
Studies Examining Intermediate- (2- to 10-Year) and Long-term (≥10-Year) LUTS in Patients Undergoing RP for Clinically Localized Prostate Cancer
| Study Authors | Length of Follow-up (y) | Study Design (Baseline?) | Number of Eligible RP Patients | LUTS Scale | Results |
|---|---|---|---|---|---|
| Intermediate-term Studies (2–10 y) | |||||
| Slova and Lepor95 | 4 | Prospective, longitudinal (baseline) | 453 | AUASI | LUTS improved in men with baseline clinically significant LUTS (AUASS > 7) No LUTS progression in men without baseline clinically significant LUTS (AUASS ≥ 7) |
| Parker WR et al68 | 5 | Prospective, longitudinal (baseline) | 382 | EPIC Irritative-Obstructive Domain | LUTS improved (88–92.1; P unknown) from baseline to 5-y follow-up |
| Miller DC et al38 | 6.2 (median) | Prospective, longitudinal cohort (no baseline) | 964 (665 RP) | EPIC Irritative-Obstructive Domain | LUTS unchanged from 2.6–6.2 y median follow-up |
| LUTS also unchanged in noncancer controls over same interval | |||||
| Long-term Studies (≥10 y) | |||||
| Prabhu V et al74 (NYUPLOS) | 10 | Prospective, longitudinal (baseline) | 1788 | AUASI | (Same findings at 10 y as Slova and Lepor95 above) |
AUASI, American Urological Association Symptom Index; AUASS, American Urological Symptom Score; EPIC, Expanded Prostate cancer Index Composite; LUTS, lower urinary tract symptoms; NYUPLOS, New York University Prospective Longitudinal Outcomes Study; RP, radical prostatectomy.